Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin in Relapsed/Refractory PMLBCL
NCT02423291Phase 2Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Oct 2013
- Primary completion
- Jul 2016
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in primary mediastinal large B-cell lymphoma (PMBCL), sponsored by Fondazione Italiana Linfomi. Started Oct 2013; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT02423291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02423291.